Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib, Vinorelbine
Sponsor: GlaxoSmithKline